Investor profile
Jonathan Behr
Private equity, Venture capital & Partner at SV Health Investors' Dementia Discovery Fund (DDF), Independent Director at Parkinson's UK
Jonathan Behr works as a Partner at SV Health Investors' Dementia Discovery Fund (DDF). The firm's known portfolio counts 11 companies.
Is Jonathan Behr a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
- Focus
- BiotechDementia therapeuticsDiagnosticsDrug DiscoveryHealthcare OperationsMedTechMedical DevicesNeuroscienceNonprofit GrantmakingPharma
Contacts
Affiliated funds' portfolios
Partner at SV Health Investors' Dementia Discovery Fund (DDF), whose known portfolio counts 11 companies
- Artios Pharma
- TRex Bio
- Therini Bio
- Imbria Pharmaceuticals
- Mestag Therapeutics
- Enara Bio
- PayMedix
- Alchemab Therapeutics
- Draig Therapeutics
- Dualitas Therapeutics
- Adimab
Independent Director at Parkinson's UK, whose known portfolio counts 7 companies
- NRG Therapeutics
- MISSION Therapeutics
- Neumora Therapeutics
- Cellestial Health
- Lucy Therapeutics
- University of Nottingham
- Keapstone Therapeutics
Investor Profile
The listing covers sector Healthcare, and focus areas Biotech, Dementia therapeutics, Diagnostics and Drug Discovery. Startups operating in these areas may find Jonathan Behr relevant.
Stage-wise, the deals at SV Health Investors' Dementia Discovery Fund (DDF) cluster around Growth, Late-Stage and Seed rounds.
What the affiliated firm has backed is the closest available signal on whether Jonathan Behr is worth approaching.
Colleagues
Dirk Landgraf
Principal
Boston, United States
Ian Garland
Non-Executive Director
Frensham, United Kingdom
Jamil M. Beg
Partner
Cambridge, United States
Brent Faduski
CFO and Partner
United States
A.J. Rossi
Investor
Boston, United States
Kate Bingham
Managing Partner
London, United Kingdom
Tom Flynn
Managing Partner
Boston, United States
Michael Balmuth
Managing Partner
Boston, United States
Paul LaViolette
Managing Partner & Chief Operating Officer
Boston, United States
Bruce Peacock
Vnture Partner
Berwyn, United States
Nikola Trbovic
Managing Partner
New York City, United States
James Costine
Director
London, United Kingdom
Charles Dunn
Principal
United Kingdom
James Garvey
Managing Partner
Boston, United States
Gregory Madden
Managing Partner
Boston, United States
Georgina Ewels
Investor
London, United Kingdom
Eugene Hill
Managing Partner
Boston, United States
Mike Ross
Senior Partner
San Mateo, United States
Frequently asked questions
Who is Jonathan Behr?
Jonathan Behr is a private equity investor and venture capital investor based in Cambridge, Massachusetts, United States, listed as Partner at SV Health Investors' Dementia Discovery Fund (DDF). The known portfolio of that firm counts 11 companies. That portfolio belongs to the firm, not to Jonathan Behr personally.
What does Jonathan Behr invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Dementia therapeutics, Diagnostics and Drug Discovery. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Jonathan Behr invest at?
SV Health Investors' Dementia Discovery Fund (DDF) appears in Growth, Late-Stage and Seed rounds across its known deals, and Jonathan Behr is listed there as Partner. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Jonathan Behr listed at?
Jonathan Behr is listed as Partner at SV Health Investors' Dementia Discovery Fund (DDF). 18 other people in the database share a firm with Jonathan Behr.
How do I contact Jonathan Behr?
An email address, a phone number and a LinkedIn page are on file for Jonathan Behr. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal